{
  "$schema": "folio-library-entry/v1",
  "id": "10665-273155",
  "blocks": [
    {
      "id": "library/10665-273155/blocks/prose-page-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 1",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../sections/page-001.md",
      "narrative": null,
      "content": "HIV DIAGNOSIS AND ARV \nUSE IN HIV-EXPOSED INFANTS: \nA PROGRAMMATIC UPDATE\nJULY 2018\nTECHNICAL REPORT",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The cover page of the July 2018 WHO technical report on HIV diagnosis and ARV use in HIV-exposed infants, a programmatic update.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 2",
      "pageStart": 2,
      "pageEnd": 2,
      "target": "../sections/page-002.md",
      "narrative": null,
      "content": "WHO/CDS/HIV/18.17\n© World Health Organization 2018\nSome rights reserved. This work is available under the Creative Commons Attribution-\nNonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/\nlicenses/by-nc-sa/3.0/igo). \nUnder the terms of this licence, you may copy, redistribute and adapt the work for non-\ncommercial purposes, provided the work is appropriately cited, as indicated below. In any use of \nthis work, there should be no suggestion that WHO endorses any specific organization, products \nor services. The use of the WHO logo is not permitted. If you",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The copyright and cataloguing page, with the document number, Creative Commons licence terms, suggested citation and standard WHO disclaimers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 3",
      "pageStart": 3,
      "pageEnd": 3,
      "target": "../sections/page-003.md",
      "narrative": null,
      "content": "1.1 EXECUTIVE SUMMARY\nNew HIV infections in children continue to occur globally \nand timely diagnosis and treatment of infants and children \nliving with HIV remain critically important. The 2016 WHO \nARV Consolidated Guidelines presented some innovative \napproaches, such as the use of nucleic acid testing (NAT) \nat or around birth for earlier diagnosis of HIV in infants, \nthe introduction of point-of-care (POC) NAT for more rapid \nand decentralized diagnosis to enable prompt antiretroviral \ntherapy (ART) initiation, and the use of enhanced \npostnatal prophylaxis (ePNP) to improve HIV preventio",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the executive summary, explaining that few countries have adopted the 2016 WHO innovations of birth testing, point-of-care NAT and enhanced postnatal prophylaxis, and that this update draws on 2017 and 2018 expert meetings to describe changing strategies for infant HIV. It is followed by a list of abbreviations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/figure-vfig-p004",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../figures/vfig-p004.webp",
      "narrative": "draft",
      "content": "Stacked horizontal bar chart of mother-to-child transmission (MTCT) rates in 2017 in the 22 Start Free, Stay Free, AIDS Free priority countries, split into 6-week transmission rate (dark blue) and post-6-week transmission rate (light blue), with totals at the bar ends; the render is cropped at the left and also includes body text above. Totals range from 26% in Indonesia, Angola and Nigeria to 5% in South Africa and Botswana; for example Indonesia 19% + 7%, Nigeria 14% + 14%, and Botswana 3% + 2%.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-273155/blocks/prose-page-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 4",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/page-004.md",
      "narrative": null,
      "content": "2.1 BACKGROUND\n2.1.1 Current status quo regarding pediatric HIV\nThe Global Plan Towards the Elimination of New HIV \nInfections among Children by 2015 and Keeping their \nMothers Alive initiative has had a substantial impact, leading \nto a 60% reduction in new pediatric HIV infections in 21 \nhigh-burden countries in sub-Saharan Africa.1,2 Nevertheless, \nthe burden of new HIV infections in children remains \nsignificant: in 2017, there were 180 000 new infections in \nchildren globally, and 70% of these children were in the \nsame 21 priority countries. The Start Free, Stay Free, AIDS \nFree framewor",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the status of paediatric HIV, noting the drop in new child infections under the Global Plan but 180 000 new infections in 2017, and the shift of mother-to-child transmission towards the postnatal period. A figure shows early and later transmission rates in the priority countries of the Start Free, Stay Free, AIDS Free framework.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 5",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../sections/page-005.md",
      "narrative": null,
      "content": "Furthermore, although pediatric ART coverage has notably \nimproved since 2010, only 51% of the estimated 1.8 \nmillion children living with HIV were receiving ART by the \nend of 2017.3 HIV-infected infants and younger children \nhave an exceptionally high mortality without treatment, \napproximately 30% by the first year and 50% by their \nsecond year of life.9 Many HIV-related deaths in infants \ncan be avoided by early identification of HIV and rapid \nART initiation. Limited availability of optimal antiretroviral \n(ARV) formulations for preventing and treating HIV \ninfection in newborn and young",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that only about half of children living with HIV were on treatment in 2017 and that untreated infants face very high mortality, then sets out the reasons for this technical update. It explains that falling transmission rates and low viremia have reduced the predictive value of nucleic acid tests, so false-positive infant diagnoses are increasingly reported. The page raises the question of introducing an indeterminate result range for early infant diagnosis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/figure-img-p006-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../images/img-p006-1.webp",
      "narrative": "draft",
      "content": "Photograph of a newborn baby swaddled in a white cloth, lying on a dark surface.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-273155/blocks/prose-page-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 6",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../sections/page-006.md",
      "narrative": null,
      "content": "A systematic review of 32 studies using an indeterminate \nrange found 14 753 non-negative test results of which \n2 436 (16.5% [95% CI 15.9–17.1%]) were indeterminate \n(data unpublished); one study14 that reported the final \ndiagnoses of indeterminate cases found that 76% of infants \nwith an initial indeterminate test result were negative \non repeat testing, suggesting these infants were not \nHIV-infected despite the initial non-negative test result. \nThese data indicate that in countries not implementing an \nindeterminate range for NAT and where MCTC rates are \nlow (<5%), 12.5% (76% of 16.5%)",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports a systematic review indicating that a sizeable share of non-negative infant test results are indeterminate, most of which prove negative on retesting, and explains the use of PCR cycle thresholds to define an indeterminate range. It closes with definitions of terms such as indeterminate, non-negative and discordant results.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 7",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../sections/page-007.md",
      "narrative": null,
      "content": "period and all infants with a positive result receive \na confirmatory test. Furthermore, those with repeatedly \nindeterminate test results should be actively tracked, \nretained, retested and their status resolved.\nFinally, POC EID testing is being implemented in several \ncountries and settings (see 3.1.3). Previously there was \nlimited evidence on how to conduct confirmatory testing of \nPOC EID positive test results, but since publication of the \n2016 WHO ARV Consolidated Guidelines10 several studies \nhave been published on its performance. Two POC EID \ntechnologies are now included on the WHO",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses confirmatory testing, noting that prequalified point-of-care infant diagnosis devices perform comparably to laboratory tests and can be used to confirm positive results, and covers management of discordant results and treatment interruption. A summary box stresses immediate retesting of indeterminate results, team support for repeated cases and confirmatory testing of all positives.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 8",
      "pageStart": 8,
      "pageEnd": 8,
      "target": "../sections/page-008.md",
      "narrative": null,
      "content": "3.1.3 Implementation of POC EID testing\nThe 2016 WHO ARV Consolidated Guidelines10 recommend \nthe use of NAT technologies for early infant HIV testing \nthat have been developed and validated for use at or near \nthe point-of-care. POC EID provides the opportunity to \nreduce test turnaround times, limit patient loss along the \nHIV testing cascade, reduce infant mortality and facilitate \ntask shifting to lower cadres of health workers at health-\ncare facilities with decentralized services. Sufficient \nevidence has been generated on the performance of these \nassays in their intended field settings",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Covers the rollout of point-of-care early infant diagnosis, citing studies in Malawi and Mozambique showing faster results and earlier treatment, and lists lessons on device placement and site selection. It also addresses birth testing, and a box urges national regulators to approve the two prequalified technologies quickly.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 9",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/page-009.md",
      "narrative": null,
      "content": "•\t Birth testing is acceptable to mothers, but challenges \narise from the increased human resources needed, the \ndifficulty of collecting blood samples in newborns, the \nneed to ensure sample collection outside of standard \nworking hours and deliver results, linkage to ART and \nthe nature of the EID system as a whole (stock-outs, \nreferral mechanisms, delayed results).\nBox 4. Implementation of birth testing: \ncountry experiences\nSouth Africa\nSouth Africa introduced NAT at birth in 2015 with \nspecific nurse training at postnatal and delivery services \nand health register updates to enable data",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes challenges of HIV testing at birth, such as staffing, sampling newborns and linkage to treatment, and describes country experiences in South Africa and Kenya. It stresses linking infected newborns to treatment with suitable formulations and the need for good leadership and coordination.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/figure-img-p010-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../images/img-p010-1.webp",
      "narrative": "draft",
      "content": "Photograph of a smiling infant in a yellow top leaning on the lap of an adult who is partly visible in the foreground.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-273155/blocks/prose-page-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 10",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../sections/page-010.md",
      "narrative": null,
      "content": "_(no text on this page)_",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A blank page with no extractable text.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 11",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/page-011.md",
      "narrative": null,
      "content": "3.1.5 Ensuring accurate interpretation of the 9-month \ntest and simplifying the testing algorithm \nThe 2016 WHO ARV Consolidated Guidelines recommend \nthat RDTs should be used to assess HIV exposure among \ninfants younger than 4 months, while HIV exposure \namong infants 4–18 months old should be ascertained \nby testing the mother. When testing of the mother is not \npossible, current guidelines emphasize the importance \nof not considering a negative RDT result from an infant \nbetween 4–18 months as a definitive test of exposure. \nImplementation issues are highlighted in Box 5.\nBased on the 2016",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Addresses interpretation of the 9-month infant test and simplification of the testing algorithm, explaining how maternal treatment, infant prophylaxis and late maternal infection can make rapid antibody tests unreliable for exposure or infection status. It sets out key points: testing mothers to establish exposure, not treating a negative infant result after 4 months as definitive, and confirming positive results with NAT.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 12",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/page-012.md",
      "narrative": null,
      "content": "3.2. ARV use for prevention and treatment \nof HIV in infants\n3.2.1 Implementation challenges to providing ePNP for \nhigh-risk infants\nThe 2016 WHO ARV Consolidated Guidelines recommend \na dual regimen of AZT and NVP which can be extended \nfor up to 12 weeks in breastfeeding infants deemed to be \nat high risk of MTCT. A high-risk infant is defined as an \ninfant whose mother was first identified as HIV-infected at \ndelivery or in the postpartum, infected during pregnancy \nor breastfeeding, started ART late in pregnancy, or did not \nachieve viral suppression by the time of delivery (Annex 4). \nAl",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the WHO recommendation of dual AZT and nevirapine prophylaxis for high-risk infants, extended to 12 weeks in breastfeeding infants, and defines which infants are high risk. It discusses the rationale based on mothers reaching viral suppression and gives guidance on whether to continue infant prophylaxis when maternal adherence is poor. It advises that prophylaxis, once stopped, should not be restarted and that attention should go to the causes of poor maternal adherence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 13",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../sections/page-013.md",
      "narrative": null,
      "content": "As more effective treatments increasingly come to be used \nin pregnant women, we can expect decreasing MTCT rates. \nHowever, some women will still be diagnosed late or have \nincident infections and this group is likely to drive most \nnew cases of HIV transmission to infants, owing to the high \nlevel of maternal virus in the absence of treatment. One \npossibility would be to provide “presumptive treatment” \nas postnatal ePNP, by administering a triple-drug regimen \nat therapeutic doses to this selected group of infants with \nthe goal of minimizing transmission and drug-resistant \nHIV (HIVDR) se",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Considers giving high-risk infants presumptive triple-drug treatment as enhanced prophylaxis, paired with testing before it starts, and describes the limited and complex options for early infant treatment. It weighs the use of fixed-dose combination tablets, noting issues such as unwanted lamivudine exposure and the need to split tablets into quarters.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/figure-img-p014-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 14,
      "pageEnd": 14,
      "target": "../images/img-p014-1.webp",
      "narrative": "draft",
      "content": "Photograph of a health worker in gloves collecting blood spots from an infant's heel onto a sample card while a woman holds the baby.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-273155/blocks/prose-page-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 14",
      "pageStart": 14,
      "pageEnd": 14,
      "target": "../sections/page-014.md",
      "narrative": null,
      "content": "provide opportunities to strengthen service delivery for \nHIV-exposed infants. Integration within a well established \nmaternal, neonatal, and child services platform, which \ntraditionally provides services closest to clients, facilitates \nmother-infant pair follow-up and reduces the cost and \ntime-visit burden on clients. The integrated information \nsystems that link mother and infant information improve \nclient tracking and facilitate continuity of care provision. \nExamples include longitudinal follow-up registers and \ncohort analysis as well as linkage with information on \ncommunit-based ser",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses integrating care for HIV-exposed infants into maternal and child health services and linked information systems, while noting pressure on staff. It also describes the role of community services and networks of women living with HIV, and lists patient-level and health system interventions to keep infants in the testing cascade.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 15",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../sections/page-015.md",
      "narrative": null,
      "content": "Box 7: Key research questions\nInfant diagnosis\n•\t \tAssess the impact of implementing an indeterminate \nrange, particularly at different testing time points, \nsample types, and technologies.\n•\t Acquire impact data to assess the added value of \nbirth testing within the EID program.\n•\t Assess the value of providing birth testing to high-risk \ninfants only.\n•\t Measure the impact of tracking tools (ie, bar codes) \nto ensure effective tracking and repeat testing at 6 \nweeks among infants testing negative at birth.\n•\t Determine if there is added value in integrating birth \ntesting with BCG vaccinatio",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists key research questions on infant diagnosis, prophylaxis and treatment, such as the value of birth testing and an indeterminate range and the dosing of new ARVs for newborns. A closing section calls for strengthening existing systems, tailoring strategies to context and gathering more programme evidence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/figure-img-p016-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../images/img-p016-1.webp",
      "narrative": "draft",
      "content": "Photograph of several women in colourful clothing and head wraps holding or carrying infants at an outdoor gathering, with men standing behind.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-273155/blocks/prose-page-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 16",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../sections/page-016.md",
      "narrative": null,
      "content": "ACKNOWLEDGEMENTS\nMeeting participants\nAdolfo Vubil (INS Mozambique), Ahmed Haeri Mazanderai \n(University of Pretoria), Andrea Ciaranello (Harvard \nMedical School), Angela Mushavi (MOH Zimbabwe), \nAnna Laura Ross (Unitaid), Archawin Rojanawiwat \n(Chulalongkorn University), Arne Kroidl (University of \nMunich), Charles Kiyaga (MOH Uganda), David Sullivan \n(USAID), Debbie Boras (London School of Hygiene and \nTropical Medicine), Deborah Persaud (Johns Hopkins \nUniversity), Elaine Abrams (ICAP), George Siberry \n(OGAC), Heather Alexander (CDC), Helen Dale (US CDC), \nJean Maritz (University of Stellen",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "An acknowledgements page listing the meeting participants and their institutions and the WHO staff involved.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 17",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../sections/page-017.md",
      "narrative": null,
      "content": "15.\t Mazanderani AH, Technau K-G, Hsiao N-Y, Maritz J, \nCarmona S, Sherman GG. Recommendations for the \nmanagement of indeterminate HIV PCR results within \nSouth Africa’s early infant diagnosis programme. \nSouthern African Journal of HIV Medicine. 2016;17(1):1-5.\n16.\t Dunning L, Francke JA, Mallampati D, MacLean RL, \nPenazzato M, Hou T, et al. The value of confirmatory \ntesting in early infant HIV diagnosis programmes \nin South Africa: A cost-effectiveness analysis. PLoS \nMedicine. 2017;14(11):e1002446.\n17.\t WHO. WHO list of prequalified in vitro diagnostic \nproducts. Geneva: World Health Orga",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Part of the reference list, citing studies on indeterminate PCR results, confirmatory and point-of-care infant testing in southern Africa, and related WHO documents.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 18",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/page-018.md",
      "narrative": null,
      "content": "EID sample no. 1\ntest no. 1\nEID sample no. 1\ntest no. 2\nNEGATIVE\nManage in accordance \nwith current guidance1\nPOSITIVE\nManage in accordance \nwith current guidance1\nINDETERMINATE\nNEGATIVE\nManage in accordance \nwith current guidance1\nPOSITIVE\nManage in accordance \nwith current guidance1\nINDETERMINATE2\nRequest a new\nsample within\n4 weeks3,4\nFurther review\nby a clinical and\nlaboratory team4\nANNEXES\nAnnex 1: Managing indeterminate test results: standard operating procedure\n1. Refer to 2016 WHO ARV Consolidated guidelines.\n2. Do not report as positive nor initiate ART, but maintain prophylaxis per c",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 1, a standard operating procedure flowchart for managing indeterminate early infant diagnosis results, including retesting within 4 weeks and team review of repeated indeterminate results.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 19",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/page-019.md",
      "narrative": null,
      "content": "Annex 2: Managing discordant results and treatment interruption\nThis option provides follow-up care to the infant for a \nminimum of 8 months after interruption of ART. Where \npossible, both EID (qualitative) and VL (quantitative) tests \nshould be performed at 4 weeks, 4 months, and 8 months \nafter treatment interruption.\nEID and viral load at 4 weeks, 4 months, and 8 months after interruption \n\nScenario a: Cessation of breastfeeding occurs after completion of the follow up post ART interruption.\nScenario b: When cessation of breastfeeding occurs before completion of the follow up post ART inte",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 2, a diagram for managing discordant results and treatment interruption, with infant NAT and viral load testing at 4 weeks, 4 months and 8 months after stopping ART and different scenarios depending on when breastfeeding ends.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 20",
      "pageStart": 20,
      "pageEnd": 20,
      "target": "../sections/page-020.md",
      "narrative": null,
      "content": "Annex 3: Simplified EID algorithm \nHIV-exposed newborn (0-2 days)\nConsider NATa,b\nNegative\nNegative\nImmediately start ARTc\nRepeat NAT to confirm \ninfection\nInfant/child is infected\nHIV-exposed infant or child \n(4-6 weeks to 18 months)\nConduct NATb \n(at 4-6 weeks or at the earliest \nopportunity thereafter)\nPositive\nPositive\nImmediately start ARTc\nRepeat NAT to confirm \ninfection\nHIV infection not detected but if infant/child \nis breastfed the risk of acquiring HIV \ninfection remains until complete cessation \nof breastfeedingd \nRegular clinical monitoring\nConduct NATb \n(at 9 months)\nAntibody tes",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 3, a simplified algorithm for early infant HIV diagnosis from birth to 18 months, showing when to do NAT and antibody tests and when to start ART. It lists key principles such as testing the mother to assess exposure and doing NAT at 9 months, with notes on final diagnosis after breastfeeding ends.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 21",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/page-021.md",
      "narrative": null,
      "content": "Annex 4: Algorithm for risk assessment \nThis algorithm was developed to support risk assessment at the time of delivery and to help identify infants at high \nand low risk:\nInfants at low risk should be given standard prophylaxis \n(NVP or AZT alone for 4–6 weeks) while those at high risk \nshould be given ePNP. In order to navigate this algorithm \nsuccessfully, clinicians will need to know a number of \nparameters from the mother’s antenatal chart: \n•\t HIV status and date of last HIV test (to identify status \nand need for testing or retesting at delivery); \n•\t if known to be positive, and ART sta",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 4, an algorithm for classifying infants as high or low risk at delivery based on the mother's HIV status, time on ART and viral load, to decide between standard and enhanced prophylaxis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 22",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../sections/page-022.md",
      "narrative": null,
      "content": "Annex 5: Dosing and formulation options for infant prophylaxis\nDosage \nforms\nDose \n0-6 weeks\nAZT plus NVP\nDose 6-12 weeks\nAZT plus NVP\nDose 6-12 weeks\nNVP only\nComments\nSyrups\nAZT \n10mg/ml\nNVP \n10mg/ml\nAZT dose 1.5ml \n(15mg) twice \ndaily\nAZT dose 6ml \n(60mg) twice daily\nNVP dose 2ml \n(20mg) once daily\n- Accurate dosing for all drugs (included for low birth \nweight newborns) and one type of formulation for the \nwhole 12-week period\n- Costly to procure and transport syrups\n- Difficult to hide in the home\n- Supplier availability may be limited\n- Might be acceptable where most women of childbearin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 5, a table comparing syrup, tablet and fixed-dose combination options for AZT and nevirapine infant prophylaxis over 0–12 weeks, with doses and pros and cons of each. It notes that AZT has no separate prophylactic dose and that presumptive treatment should follow age-appropriate WHO dosing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/figure-img-p023-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../images/img-p023-1.webp",
      "narrative": "draft",
      "content": "Photograph of an infant in a red top looking over the shoulder of a woman wearing an orange veil.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-273155/blocks/prose-page-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 23",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../sections/page-023.md",
      "narrative": null,
      "content": "_(no text on this page)_",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A blank page with no extractable text.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-273155/blocks/prose-page-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 24",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/page-024.md",
      "narrative": null,
      "content": "For more information, contact:\nWorld Health Organization\nDepartment of HIV/AIDS\n20, avenue Appia\n1211 Geneva 27\nSwitzerland\nWHO/CDS/HIV/18.17 \nE-mail: hiv-aids@who.int\nwww.who.int/hiv",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The back cover, giving contact details for the WHO Department of HIV/AIDS in Geneva and the document number.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
